Literature DB >> 25124231

Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand.

Zuzana Obertová1, Nina Scott, Charis Brown, Alistair Stewart, Ross Lawrenson.   

Abstract

OBJECTIVE: To examine temporal trends and current survival differences between Māori and non-Māori men with prostate cancer in New Zealand (NZ). PATIENTS AND METHODS: A cohort of 37,529 men aged ≥ 40 years diagnosed with prostate cancer between 1996 and 2010 was identified from the New Zealand Cancer Registry and followed until 25 May 2011. Cause of death was obtained from the Mortality Collection by data linkage. Survival for Māori compared with non-Māori men was estimated using the Kaplan-Meier method, and Cox proportional hazard regression models, adjusted for age, year of diagnosis, socioeconomic deprivation and rural/urban residence.
RESULTS: The probability of surviving was significantly lower for Māori compared with non-Māori men at 1, 5 and 10 years after diagnosis. Māori men were more likely to die from any cause [adjusted hazard ratio (aHR) 1.84, 95% confidence interval (CI) 1.72-1.97] and from prostate cancer (aHR 1.94, 95% CI 1.76- 2.14). The aHR of prostate cancer death for Māori men diagnosed with regional extent was 2.62-fold (95% CI 1.60-4.31) compared with non-Māori men. The survival gap between Māori and non-Māori men has not changed throughout the study period.
CONCLUSION: Māori men had significantly poorer survival than non-Māori, particularly when diagnosed with regional prostate cancer. Despite improvements in survival for all men diagnosed after 2000, the survival gap between Māori and non-Māori men has not been reduced with time. Differences in prostate cancer detection and management, partly driven by higher socioeconomic deprivation in Māori men, were identified as the most likely contributors to ethnic survival disparities in NZ.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  indigenous; outcomes; prostate cancer; survival; temporal changes

Mesh:

Year:  2015        PMID: 25124231     DOI: 10.1111/bju.12900

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Updates in the care and management of prostate cancer: highlights from the 2013 prostate cancer world congress, august 6-10, 2013, melbourne, australia.

Authors:  Marnique Basto; Aine Goggins; Stacy Loeb
Journal:  Rev Urol       Date:  2013

2.  Uric acid: a modulator of prostate cells and activin sensitivity.

Authors:  Febbie Sangkop; Geeta Singh; Ely Rodrigues; Elspeth Gold; Andrew Bahn
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

3.  Treatment modalities for Māori and New Zealand European men with localised prostate cancer.

Authors:  Zuzana Obertová; Ross Lawrenson; Nina Scott; Michael Holmes; Charis Brown; Chunhuan Lao; Leanne Tyrie; Peter Gilling
Journal:  Int J Clin Oncol       Date:  2015-01-06       Impact factor: 3.402

4.  The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.

Authors:  Ross Lawrenson; Zuzana Obertová; Charis Brown; Peter Fong; Leanne Tyrie; Nina Scott; Michael Holmes
Journal:  J Cancer       Date:  2014-02-14       Impact factor: 4.207

5.  Comparing cancer incidence, stage at diagnosis and outcomes of First Nations and all other Manitobans: a retrospective analysis.

Authors:  Tara C Horrill; Lindsey Dahl; Esther Sanderson; Garry Munro; Cindy Garson; Carole Taylor; Randy Fransoo; Genevieve Thompson; Catherine Cook; Janice Linton; Annette S H Schultz
Journal:  BMC Cancer       Date:  2019-11-06       Impact factor: 4.430

6.  Ethnic inequalities in cancer incidence and mortality: census-linked cohort studies with 87 million years of person-time follow-up.

Authors:  Andrea M Teng; June Atkinson; George Disney; Nick Wilson; Diana Sarfati; Melissa McLeod; Tony Blakely
Journal:  BMC Cancer       Date:  2016-09-26       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.